NewAmsterdam Pharma Company N.V. Ordinary Shares Working Capital to Net Assets Ratio
NewAmsterdam Pharma Company N.V. Ordinary Shares working capital to net assets ratio. NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) has a Working Capital to Net Assets ratio of 92.6% as of September 2025. Working capital of $674.06 Million (current assets of $732.33 Million minus current liabilities of $58.27 Million) is measured against net assets of $728.07 Million. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of NewAmsterdam Pharma Company N.V. Ordinary Shares (2020–2024)
Working capital to net assets ratio of NewAmsterdam Pharma Company N.V. Ordinary Shares from 2020 to 2024. This chart shows how NewAmsterdam Pharma Company N.V. Ordinary Shares's Working Capital to Net Assets ratio has evolved across 5 annual periods from 2020 to 2024. As of September 2025, the ratio stands at 92.6%, reflecting working capital of $674.06 Million against net assets of $728.07 Million USD. Explore NewAmsterdam Pharma Company N.V. Ordinar (NAMS) long-term investment share to see how much of total assets are deployed in long-term investments.
NewAmsterdam Pharma Company N.V. Ordinary Shares Working Capital to Net Assets Ratio by Year (2020–2024)
NewAmsterdam Pharma Company N.V. Ordinary Shares working capital to net assets ratio by year from 2020 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for NewAmsterdam Pharma Company N.V. Ordinary Shares from 2020 to 2024, covering 5 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see NewAmsterdam Pharma Company N.V. Ordinar balance sheet assets.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 99.9% | $756.50 Million | $757.50 Million | $863.41 Million | $106.92 Million | ▼ -3.1 pp |
| 2023 | 102.9% | $296.89 Million | $288.39 Million | $346.79 Million | $49.90 Million | ▲ +0.2 pp |
| 2022 | 102.8% | $441.92 Million | $430.07 Million | $477.98 Million | $36.06 Million | ▲ +4.4 pp |
| 2021 | 98.4% | $55.72 Million | $56.63 Million | $66.96 Million | $11.24 Million | ▲ +97.1 pp |
| 2020 | 1.3% | $1.63 Million | $127.46 Million | $1.87 Million | $236.52K | — |